Ph II of Vinflunine and Cetuximab in Second Line Treatment of NSCLC

OBJECTIVES: Primary * Estimate the objective response rate in patients receiving vinflunine and cetuximab as second-line therapy for stage IIIB or IV non-small cell lung cancer. Secondary * Determine the progression-free survival of patients treated with this regimen. * Determine the safety of this regimen in these patients. * Determine the overall survival of patients treated with this regimen. * Determine the duration of overall response in these patients. OUTLINE: This is a multicenter study. Patients receive vinflunine IV over 15-20 minutes on day 1 and cetuximab IV over 60-120 minutes on days 1, 8, and 15. Treatment repeats every 21 days for 4 courses in the absence of disease progression or unacceptable toxicity. Patients with responding disease may receive additional courses beyond 4 courses at the discretion of the principal investigator. After completion of study therapy, patients are followed periodically for 6 months.